Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 03 - 29 symbols : Pfe save search
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
Published: 2022-03-29 (Crawled : 01:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
trial potential positive results topline license phase 3 ulcerative colitis
Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
Published: 2022-03-29 (Crawled : 18:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: 1.83%
H: 3.58%
C: 1.77%
covid-19 authorization vaccine order emergency use authorization
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg
Published: 2022-03-29 (Crawled : 18:00) - biospace.com/
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: -1.87%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
fda approval hiv order
Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential
Published: 2022-03-29 (Crawled : 11:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
trial potential positive results phase 3 topline ulcerative colitis
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.